Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ford Motor Company (F) vs Sana Biotechnology Inc (SANA) Price & Performance

Ford Motor CompanyTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Ford Motor Company vs Sana Biotechnology Inc — how do they compare? Ford Motor Company trades at $13.83 (market cap $55.75B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Ford Motor Company is far larger — about 49.3× Sana Biotechnology Inc's market cap, and Ford Motor Company pays a 4.29% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

FSANA
Market Cap
$55.75B$1.13B
Sector
Consumer CyclicalHealth
52-Week High
$17.44$5.92
52-Week Low
$11.21$2.68
Enterprise Value
$187.71B$1.05B
Dividend Yield
4.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ford Motor Company

Ford Motor Company (F) trades at $14.015, up 0.25% on the day, with a bearish technical signal and mixed earnings history including a recent Q3 2026 miss. The company reported a net loss of $8.18 billion for 2025, with negative profit margins, but maintains strong operating cash flow of $21.28 billion. Recent news highlights the upcoming affordable Fathom EV truck priced around $28,000, targeting market share gains amid high vehicle prices.

The outlook is cautious; while analyst consensus is a Buy with a $16.18 price target, fundamental weaknesses like negative ROE and net income margin pose risks. The EV transition and competitive pressures are key challenges, but the dividend yield and cash flow stability offer some investor appeal. Execution on new models like the Fathom is critical for a turnaround.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.

Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ford Motor Company

Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.

Read more on F

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA